Maze Therapeutics launches with nearly $200M to explore genetic modifiers’ role in disease
Third Rock and ARCH led the launch of the company, which will look at ways to target genetic modifiers that can protect against certain diseases.
ARCH Venture Partners looks to raise $600M in its 10th fund
The Chicago-based life sciences venture capital firm had previously raised $408.4 million for its ninth fund, in 2016. Others - including Pfizer and Taiho - have recently boosted their VC investment pools as well.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Nebula Genomics raises $4.3M in seed capital to fund blockchain-based data marketplace
The company plans to use blockchain and other technologies to develop the genomic data marketplace, under a partnership with Veritas Genetics.
ApoGen increases 2016 Series A funding round to $11 million
Company draws $4 million in additional funding from Merck KGaA's venture capital arm and other investors.
Neurology startup Magnolia Neurosciences raises $31M in Series A round
Company seeks to block components of reactivated programmed cell death process implicated in Alzheimer's disease.
Scripps spin-out Vividion launches with $50M
A startup from the Scripps Research Institute has raised a $50 million Series A to "expand the druggable proteome." Led by ARCH and Versant Ventures, the sizeable investment reflects the potential of both the platform and the countless therapeutic candidates it could produce.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Life sciences investors ARCH Venture Partners raising $400M for ninth fund
The amount being raised in this newest fund is in line with ARCH's previous funds: Its eighth, for instance, raised $410 million in 2014 and its seventh raised $400 million in 2007.
Doug Williams’ Codiak Biosciences gets $61M Series B for exosome work
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
Arch Venture Partners plans to fund “wild-ass ideas” with new, $400 million venture fund
Tech venture behemoth Arch Venture Partners has announced its eighth venture fund just closed with more than $400 million in subscriptions and, as co-founder and managing director Robert Nelson just told Forbes, it’s looking to fund companies with “contrarian philosophies.” Alex Konrad over at Forbes writes: That money will go to funding companies that cofounder and […]
Polaris, ARCH Venture Partners put $15M behind launch of deCODE genetics spinoff NextCODE
Sequencing the genome is one thing, but applying the data produced from that process to clinical care is a whole other thing. A new startup called NextCODE Health has launched with $15 million and a license to use the genomics platform of deCODE genetics to develop sequence-based clinical diagnostics. deCODE, a once-bankrupt Icelandic company now […]
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
RNAi drug delivery company secures $1.6M for endosomal escape technology
PhaseRx is developing a RNAi drug delivery system that uses synthetic polymers to help RNAi-based therapeutics escape endosomes and reach cell cytoplasm.
Kidney disease drug developer Sorbent Therapeutics raises $21M
Sorbent Therapeutics Inc. has raised a $21 million Series B round to fund Phase 2 clinical trials of a non-absorbed polymer-based drug for end-stage renal disease. The company’s renal disease drug, called CLP 1001, isn’t absorbed into the bloodstream and works by absorbing sodium and fluid from a patient’s gastrointestinal tract, said CFO and co-founder […]
Michigan’s Lycera Corp. raises a $36 million Series A round
The autoimmune drug-maker Lycera will fund testing on two of its drugs. One drug will go through Phase II proof-of-concept studies while another will move into Phase I clinical trials, according to the release.